A new treatment option has become available for severe epilepsy: fenfluramine, which is now available on the NHS for children and adults living with Lennox–Gastaut syndrome (LGS).
Trevor Graham, Professor of Genomics and Evolution and the Director of the Centre for Evolution and Cancer at the Institute of Cancer Research, London, describes efforts to incorporate genome sequencing for cancer detection and treatment.
We all have a unique face, fingerprint, voice, and signature, so why wouldn’t we have a unique response to the medicine and treatments we receive? Mark Hitchman, Managing Director at Canon Medical Systems UK, explores this question.
Our bones are designed to remodel themselves; this is a lifelong process involving the bones adjusting to maintain strength, repair damages, and react to specific stress'.
Rachael Lee, Acting Programme Manager of the National Wound Care Strategy Programme (NWCSP), discusses the challenges in wound care provision and the efforts to...
A new treatment, Sotatercept, for pulmonary arterial hypertension (PAH) has recently been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA).
Tarlatamaba, a new treatment for adult patients with small cell lung cancer (SCLC), has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA).
Infections are the second leading cause of death in cancer patients, after the cancer itself; Zisis Kozlakidis and Shalini Jayasekar Zurn discuss the challenges surrounding the interplay between cancer and antimicrobial resistance (AMR).
Inflammatory skin diseases like psoriasis involve interactions between skin cells (keratinocytes) and immune cells, which leads to chronic inflammation, disfiguring skin lesions, and systemic effects.
A substantial investment totalling £55 million, made possible through funding from the Northern Ireland Executive alongside various consortium partners, is set to advance innovation within the critical field of precision medicine.
The NHS in England has introduced a new therapy that hopes to transform the lives of hundreds of adults living with X-linked Hypophosphatemia (XLH), this rare genetic disorder causes severe bone, dental, and skeletal issues.
Recent Phase 3 trial results for icotrokinra (JNJ-2113), an investigational oral peptide from Johnson & Johnson, have shown the drug’s potential to offer significant relief for patients suffering from moderate-to-severe plaque psoriasis.
The NHS is looking for volunteers as part of the three cancer projects that have been selected as part of the NHS DigiTrials initiative. Almost 150,000 volunteers will take part in these trials to help transform cancer treatment.
